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Abstract
An association between leukoencephalopathy, a disease of the white matter of the brain, and smoking heroin is
well recognized. This paper describes 27 cases of leukoencephalopathy identified in two cities in British Columbia,
Canada 2001-2006; the largest number of geographically and temporally defined reported cases in North America.
Twenty cases of leukoencephalopathy were identified in and around Vancouver with onset dates December 2001
to July 2003; seven further cases were identified in Victoria September 2005-August 2006. Twenty (74%) of all cases
were male, two couples were reported and eleven cases (55%) had Asian ethnicity. One case reported smoking
heroin on a single occasion and developed mild symptoms; all other cases were hospitalized. Thirteen (48%) cases
died; all had smoked heroin for a minimum of 3 years. Testing of one available heroin sample identified no
substance other than common cutting agents.
Although a specific etiology was not identified our study supports the theory of an intermittent exposure to a
toxic agent added to the heroin or a combustion by-product. It also suggests a dose response effect rather than
genetic predisposition. Collaboration with public health, health professionals, law enforcement and persons who
use illegal drugs, will facilitate the early identification of cases to enable timely and complete follow-up including
obtaining samples. Testing of implicated heroin samples may allow identification of the contaminant and therefore
prevent further cases. It is therefore important to ensure key stakeholders are aware of our findings.
Introduction
Leukoencephalopathy refers to disease of the white mat-
ter of the brain and therefore can involve motor, sen-
sory, and visual systems. Leukoencephalopathy can also
disrupt cognitive and emotional function. There are
many etiologies of leukoencephalopathy, including
genetic disorders, cerebrovascular disease, eclampsia and
toxic exposures. The clinical manifestation of the disease
is a reflection of the areas of the brain involved in the
disease process. Clinical features range from inattention,
forgetfulness and personality changes, to dysarthria,
ataxia, dementia, coma and death [1]. Toluene, ethanol,
cocaine, methylenedioxymethamphetamine (MDMA or
“ecstasy”) and heroin have all been associated with toxic
leukoencephalopathies [1]. Toxic exposure from heroin
induced leukoencephalopthy typically involves the occi-
pital lobes and cerebellum bilaterally, characteristic sym-
metric patterns can be seen on neuroimaging [2-5].
An association between leukoencephalopathy and
smoking heroin has been recognized for over 25 years,
although the exact pathogenesis is still not well under-
stood. In ‘chasing the dragon’, heroin is placed on a
piece of aluminium foil, heated with a flame from
below, and the resulting vapour (pyrolysate) is inhaled
with a straw or other tube-like structure. The practice
was first recognized in Hong Kong in the 1950’s but has
now spread to users worldwide [6].
Although the practice of ‘chasing the dragon’ is not
uncommon, the associated leukoencephalopathy has
been rarely reported. The first and largest outbreak of
leukoencephalopathy linkedt oc h a s i n gt h ed r a g o nw a s
reported 1982 in the Netherlands, and included 47
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cases and small case clusters (ranging from 1-4 cases)
have been report ed in Taiwan [7,8], Hong Kong [9],
other European countries [4,5,10-13], the United States
[3,14,15] and Canada [16]. Three larger clusters have
been identified in China [17-20]. The primary hypothesis
is that leukoencephalopathy is caused by a contaminant
in the heroin or a combustion by-product [6,21,22].
Despite multiple attempts to identify a contaminant in
heroin samples; no causative agent has yet been
identified.
Between December 2001 and July 2003, 20 cases of
leukoencephalopathy linked to heroin inhalation were
identified in and around Vancouver, British Columbia
(BC) Canada. An investigation was initiated at the time;
but no causative agent was identified. Case reports were
created to describe the clinical, pathologic, and imaging
findings and awareness campaigns were initiated.
In the fall of 2005, further cases of leukoencephalopa-
thy were reported in Victoria, BC on Vancouver Island.
An investigation was initiated in order to describe the
epidemiology of the new cases. The purpose of this
paper is to characterize all cases of heroin associated
leukoencephalopathy identified since 2001 to date in BC
in order to guide future research and public health
actions.
Methods
A case of heroin associated leukoencephalopathy was
defined as:
A person with clinical features of toxic leukoencepha-
lopathy +/- neuroimaging with white matter changes
typical of heroin-associated leukoencephalopathy
AND a history of chasing the dragon
AND a resident of BC or reported obtaining heroin
in BC
A case report form (which collected demographic,
drug use, and clinical information) and a fact sheet for
physicians and the public were developed. The Provin-
cial Health Officer notified BC neurologists about the
cases of leukoencephalopathy associated with ‘chasing
the dragon’ through the provincial specialty society list
serve. Medical Health Officers throughout the province
were also informed; they in turn notified the hospital
Emergency Department heads and family physicians in
their health regions. All physicians were requested to
notify cases to local public health, which ensured the
completed case report form was sent to the BC Centre
for Disease Control.
Where possible, charts of cases were reviewed and
interviews were conducted with the case or next of kin.
Abstracted information included: sex, date of birth,
residence and ethnicity, medical, social and drug his-
tories, date of symptom onset, date of hospital admis-
sion, clinical course and outcome. Cases were asked if a
heroin sample was available for testing. A process was
arranged for samples to be transported by the police
to the Health Canada Drug Analysis Laboratory for
content analysis using liquid chromatography-mass
spectrometry.
Results
In addition to 20 cases identified in and around Van-
couver with onset dates between December 2001 - July
2003, a further 7 cases were identified in Victoria with
onset between September 2005- August 2006 (Figure 1).
All cases, except one, were hospitalized. Thirteen (48%)
died and 20 (74%) were male (Table 1). Two heterosex-
ual case-couples were reported; one pair in Vancouver
and one in Victoria. Eleven Vancouver cases (55%)
reported Asian ethnicity; while all Victoria cases were
Caucasian.
Patients typically presented with symptoms of cerebel-
lar dysfunction such as ataxia, and all cases reported dif-
ficulty with speech. The clinical and imaging findings of
three of the Vancouver cases are presented elsewhere
[2]. The date of death was available for seven of the
deceased, for these the median time between symptom
onset and death was 54 days (range: 16-408 days).
Drug histories were obtained for 18 (67%) cases. One
case that reported smoking on a single occasion devel-
oped mild symptoms and was not hospitalized. Exclud-
ing this case the mean duration of chasing the dragon
was 9.5 years (range 0.5 - 30 years). Of the cases that
died, the minimum time of smoking heroin was three
years. Use of other illicit drugs was reported in both
Vancouver and Victoria cases (cocaine, marijuana,
ecstasy, and crystal methamphetamine). Three (43%) of
the Victoria cases reported that smoking heroin was
their only type of illicit drug use. At least six (86%) of
the Victoria cases were taking methadone at the time of
symptom onset; and five (25%) Vancouver cases
reported using methadone, although these data are
incomplete.
Drug supply information was available for four (57%)
of the Victoria cases; all reported obtaining heroin
through telephone order and home delivery (dial-
a-dope) from a male Asian supplier. The first three
Vancouver cases also reported being supplied by
an Asian supplier through dial-a-dope but data are
incomplete for the rest of Vancouver cases.
Three (47%) of the Victoria cases reported commercial
painting as an occupation. No associations were found
with type of aluminium foil (commonly purchased at the
local supermarket); or with other underlying conditions
or medication other than methadone. No difference
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Page 2 of 5in colour, texture or smell of the heroin was reported by
the cases. Apart from the two couples no cases reported
knowing anyone else with similar symptoms. One heroin
sample from a Vancouver case was tested with only com-
mon cutting agents identified.
Discussion
We have characterized 27 cases of leukoencephalopathy
associated with ‘chasing the dragon’.T h i si st h el a r g e s t
number of cases reported in North America which are
temporally and geographically defined. Although an
etiologic agent has not been identified, we have a better
understanding of the population at risk. The age, sex
and ethnicity of our cases are consistent with the demo-
graphic profiles in other published reports. Forty-one
percent of BC cases were Asian; this preponderance,
also found in other studies, is likely representative of
persons who ‘chase the dragon’ [6].
Identification of two heterosexual case-couples sug-
gests that the risk factors for leukoencephalopathy are
more likely to be substance related rather than due to
genetic predisposition. The distribution of the cases in
place and time suggests a common intermittent expo-
sure. Substances added to the heroin may be an inert
‘cutting agent’ such as caffeine, lactose or mannitol to
increase the volume and hence profit, or an ‘adulterant’,
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Figure 1 Leukoencephalopathy cases associated with chasing the dragon in British Columbia, 2001-2006 by symptom onset date
(n = 27).
Table 1 Demographic and outcome variables among leukoencephalopathy cases in BC (n = 27)
Variable Vancouver (n = 20) Victoria (n = 7) All cases (n = 27) Vancouver vs. Victoria
Mean Range Mean Range Mean Range P-value
†
Age (years) 36 32 - 42 32 21 - 51 33 21 - 51 0.220
N % N % N % P-value
‡
Sex: Male 15 75 5 71 20 74 1.000
Ethnicity: Asian 11 55 0 0 11 41 0.022*
Hospitalized 19 95 7 100 26 96 1.000
Deceased 10 50 3 43 13 48 1.000
† P-value determined using t-test.
‡P-value determined using Fisher’s exact test.
*Statistically significant difference (p < 0.05).
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dial-a-dope delivery system identified by some cases
may involve additional persons in the supply and deliv-
ery chain (i.e., from the dealer to the deliverer) and
increase the risk of contaminants being added, either for
profit or to retain some drug for personal use. It is unli-
kely that the contaminant is added to cause intentional
harm as it is in the best interest of the dealer to main-
tain his/her client base[24].
According to a recent report from the UN Office of
the Drug Commission, 96% of heroin seizures (2002-
2007) in the US originated from Mexico and Columbia;
whereas 98% of heroin seized in Canada originated from
Southwest Asia [25]. Although the source of heroin dif-
fers between Canada and US, and the epidemiology and
prevalence of ‘chasing the dragon’ in BC is poorly
understood, the incidence and risk of the resultant leu-
koencephalopathy is clearly low. We believe this indi-
cates the contaminant is likely added close to the final
delivery stage, rather than at the original source. How-
ever there is likely under-reporting as physicians are
required to actively report the condition to public
health, some cases may have been mild and sponta-
neously recovered and others attributed to other
etiologies.
T h ep u r i t yo fs t r e e th e r o i ni nB C ,d e t e r m i n e db y
Health Canada, Drug Analysis Service, has increased
from 5-10% in the 1970’s, to greater than 60% [26].
However, heroin used for smoking is usually 30% to
40% pure as higher grade cuts char too quickly for effec-
tive smoking. Heroin is also reported to be increasingly
available in the base form which is not amenable for
injection [27]. Smoking heroin in North America was
becoming established prior to the knowledge of the
risks of HIV associated with injecting [28]. Gossop et al
found that chasing the dragon was a well-established
method of using heroin in certain populations, not
merely a pre-injection phase of heroin addiction [29].
Therefore, drug availability, attitudes to using needles,
stigma and the potential of disease transmission related
to injection drug use may have led to increased smoking
rather than injection of heroin. This illustrates the
potential for further cases to occur.
One case with a single brief exposure to inhaling her-
oin pyrolysate required outpatient support only. This
finding was similar to a case report in the literature of a
patient with an isolated exposure who had a complete
recovery, and is consistent with a dose-response rela-
tionship [3,12]. Clarity of quantity and purity of heroin
used by cases would allow a better understanding of a
dose-response relationship.
Reported clusters of leukoencephalopathy have been
associated with smoking heroin. However isolated cases
of leukoencephalopathy associated with using heroin
and heroin and cocaine intravenously [30-32], and one
case of leukoencephalopathy associated with heroin
ingestion occurring in a 2 year old child have been
reported [33]. The development of disease associated
with other routes of administration highlights the lack
of knowledge about the etiological agent and the impor-
tance of determining its identity.
The etiology of heroin-related toxic leukoencephalo-
pathy requires further research and public health invol-
vement. The severity of the outcome and lack of
curative treatment highlights the importance of future
investigations. Current therapy with coenzyme Q and
vitamin supplements is anecdotal only [34]. Previous lit-
erature has been mostly published in neurology and
radiology journals as clinical case reports; isolated cases
make it difficult to determine risk factors for this condi-
tion. Research into the prevalence of ‘chasing the dra-
gon’ will help determine the potential risk for further
outbreaks and may indicate a need to modify both edu-
cational, treatment and support services for this group
of heroin users. Although a specific etiology has not
been identified, a toxic agent added to the heroin, or a
combustion by-product, remain the leading theories
[6,21,22].
Limitations of our study include incomplete case and
drug information. This may be related to the inability of
cases to communicate at presentation and the rapid
decline in mental state of some. Also, the illicit nature
of drug use may cause concerns about sharing informa-
tion regarding other drug users or the source of heroin.
Family members may have little prior knowledge of the
case’s drug use, limiting the information provided
through collateral history. The delay between heroin use
and symptom onset also reduces the likelihood that
implicated heroin is available for testing.
Recognizing the difficulties inherent in studying such a
sporadically occurring condition, a serious effort to
determine etiology may require both reactive and pro-
spective approaches. Collaboration with public health,
health professionals, law enforcement and persons who
use illegal drugs, would facilitate the early identification
of cases to enable timely and complete follow-up includ-
ing obtaining heroin samples. A pre-arranged process
for transporting and testing implicated heroin samples
may allow identification of the contaminant and there-
fore prevent further cases. Purity and contaminant
sampling programs for street drugs could also be con-
sidered. It is therefore important to ensure key stake-
holders are aware of these findings and the association
of leukoencephalopathy and heroin smoking.
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